We are thrilled to announce that we have been awarded a grant from the Massachusetts Life Sciences Center (MLSC) for a collaborative project with Virion Therapeutics, LLC. Virion is at the forefront of developing novel T cell-based immunotherapies designed to enhance and broaden CD8+ T cell responses against tumors and chronic infections, including their lead clinical program, VRON-0200, which targets chronic HBV infection. Our multicellular liver organoid model will play a key role in testing these therapeutic agents. By integrating these advanced technologies, we aim to accelerate clinical development and advance toward a functional cure for the over 300 million individuals affected by chronic HBV.
https://www.masslifesciences.com/healey-driscoll-administration-announces-nearly-20-million-in-life-sciences-funding-to-advance-innovation-in-research-and-development-data-science-drug-delivery-and-womens-health/